secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2024-06-18T23:59:59+00:00
Accession:  0001404644-24-000073
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene doses first patient in high-dose cohort of NGN-401; safety data positive
--------------------------------------------------------------------------------

- First patient in Cohort 2 received high-dose NGN-401 in May 2024; well-tolerated to date.
- Low-dose cohort (3 patients) shows no new treatment-related adverse events; all AEs mild/Grade 1.
- No signs of MeCP2 overexpression toxicity, including in patient with mild genetic variant.
- Company expects interim efficacy data from low-dose cohort in Q4 2024.
- Neurogene is participating in FDA's START Pilot Program to accelerate NGN-401 development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464424000073/0001404644-24-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464424000073/ngne-20240618.htm
  HTML page:      https://secwatch.observer/filing/0001404644-24-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer